So, while SCCs with high levels of TrkB–T1 mRNA may make up a subtype of SCC, where the same suite of pathways is enriched, the tumor behavior continues to depend on how the cell responds to activation of those pathways. This evidence concerns the gene NTRK2 and neoplasm.